The Columbia River Oncology Program (CROP), a Community Clinical Oncology Program (CCOP) currently in its 22nd year, is a consortium of four health care systems in the metropolitan Portland, Oregon/Vancouver, Washington area. These health care systems encompass: Adventist Medical Center, Legacy Health System, Providence Health System, and Southwest Washington Medical Center. CROP'S specific aims are: 1) Enhance the health of our community by providing and promoting cancer treatment, cancer prevention and cancer control research studies, 2) Seek opportunities to mirror the diversity of our community by providing complementary and holistic clinical research studies, 3) Advocate for and participate in clinical trials providing symptom management, improved quality of life, and palliative care for our cancer patient population, 4) Increase our physician alliances and commitments to clinical trials and increase accrual goals, and 5) Expand participation of minorities and the underserved population to participate in cancer prevention, cancer control and treatment studies. CROP currently affiliates with seven research bases: COG, MDACC, NCCTG, NSABP, RTOG, SWOG, and URCC. All are multi-specialty cooperative groups that supply CROP with NCI approved cancer prevention, cancer control and cancer treatment protocols. The established functioning operational status of CROP includes an Executive Board with representative committee structure, a central office, and actively participating hospital systems. The central office staff coordinates the administrative aspects of CROP, the large cancer prevention studies and quality improvement activities. The Clinical Trial Nurses and Clinical Research Associates employed by the consortium hospitals recruit patients to cancer control and treatment protocols collect and submit data to the research bases, participate in the quality improvement process, and actively participate in the research base meetings. Each organization employs a pharmacist to manage the investigational agents for CROP.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA045377-26
Application #
8291410
Study Section
Special Emphasis Panel (ZCA1-SRRB-Y (J1))
Program Officer
O'Mara, Ann M
Project Start
1987-08-28
Project End
2014-05-31
Budget Start
2012-06-01
Budget End
2013-05-31
Support Year
26
Fiscal Year
2012
Total Cost
$986,419
Indirect Cost
$324,168
Name
Providence Portland Medical Center
Department
Type
DUNS #
099142093
City
Portland
State
OR
Country
United States
Zip Code
97213
Yao, S; Sucheston, L E; Zhao, H et al. (2014) Germline genetic variants in ABCB1, ABCC1 and ALDH1A1, and risk of hematological and gastrointestinal toxicities in a SWOG Phase III trial S0221 for breast cancer. Pharmacogenomics J 14:241-7
Kernstine, Kemp H; Moon, James; Kraut, Michael J et al. (2014) Trimodality therapy for superior sulcus non-small cell lung cancer: Southwest Oncology Group-Intergroup Trial S0220. Ann Thorac Surg 98:402-10
Flaherty, Lawrence E; Othus, Megan; Atkins, Michael B et al. (2014) Southwest Oncology Group S0008: a phase III trial of high-dose interferon Alfa-2b versus cisplatin, vinblastine, and dacarbazine, plus interleukin-2 and interferon in patients with high-risk melanoma--an intergroup study of cancer and leukemia Group B, Ch J Clin Oncol 32:3771-8
Bepler, Gerold; Zinner, Ralph G; Moon, James et al. (2014) A phase 2 cooperative group adjuvant trial using a biomarker-based decision algorithm in patients with stage I non-small cell lung cancer (SWOG-0720, NCT00792701). Cancer 120:2343-51
Allen, Jeffrey W; Moon, James; Redman, Mary et al. (2014) Southwest Oncology Group S0802: a randomized, phase II trial of weekly topotecan with and without ziv-aflibercept in patients with platinum-treated small-cell lung cancer. J Clin Oncol 32:2463-70
Goldkorn, Amir; Ely, Benjamin; Quinn, David I et al. (2014) Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer. J Clin Oncol 32:1136-42
Carson 3rd, William E; Unger, Joseph M; Sosman, Jeffrey A et al. (2014) Adjuvant vaccine immunotherapy of resected, clinically node-negative melanoma: long-term outcome and impact of HLA class I antigen expression on overall survival. Cancer Immunol Res 2:981-7
Gralow, Julie R; Barlow, William E; Lew, Danika et al. (2014) A phase II study of docetaxel and vinorelbine plus filgrastim for HER-2 negative, stage IV breast cancer: SWOG S0102. Breast Cancer Res Treat 143:351-8
Smerage, Jeffrey B; Barlow, William E; Hortobagyi, Gabriel N et al. (2014) Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500. J Clin Oncol 32:3483-9
Quinn, David I; Tangen, Catherine M; Hussain, Maha et al. (2013) Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial. Lancet Oncol 14:893-900

Showing the most recent 10 out of 123 publications